Research Applications

Connect the scientific question with an antigen-defined eDC configuration and a relevant functional readout.

Antigen-specific T cell responses

Start with the study antigen and relevant HLA context. Choose readouts that distinguish a general activation signal from a response to the selected antigen.

Planning questionConsideration
What is the intended recognition event?Define antigen, HLA context and immune cell source
How will specificity be assessed?Include antigen-negative or irrelevant antigen comparisons where appropriate
What will be measured?Choose activation, expansion or specificity readouts that suit the study
Explore antigen-expressing eDC lines

Target cell cytolysis

Connect the APC configuration to a paired target cell model. The antigen and HLA status of the targets determine which comparisons are interpretable.

Measure cytolysis across defined effector-to-target ratios, with target-only background and suitable antigen/HLA controls. Normalize according to the validated assay method used for the study.

View hTERT & MAGEA3 research examples

APC gene function studies

Use a custom eDC configuration to investigate the effect of a selected gene modification, including KO. Define the expected biological question, confirmation method and functional endpoint before development.

A matched control and comparable antigen expression, culture state and passage context help interpret an observed change.

Explore custom eDC engineering

Peptide–HLA target nomination

Test whether a candidate peptide–HLA complex is immunogenic and recognized in an HLA-dependent way, before an antibody, CAR-T, ADC or T cell engager is built against it. Targeting the complex rather than a surface protein can add specificity.

Planning questionConsideration
Is the complex immunogenic?T cell response to the antigen-expressing eDC, with irrelevant antigen and no-peptide controls
Is it presented on tumor cells?Add presentation evidence such as immunopeptidomics, or recognition of targets that express the endogenous antigen
How specific is the binder?Test the binder against related peptide–HLA complexes and against antigen-negative, HLA-mismatched cells
See how eDC evidence fits each modality

Screening immunomodulatory biologics

eDCs keep a mature phenotype with costimulatory molecules such as CD40. Agonist and checkpoint antibodies can be compared by their effect on APC activation and T cell priming.

Planning questionConsideration
Is the target present?Confirm expression, for example CD40 or PD-L1, on the eDC line before screening
What is measured?APC activation markers, cytokines such as IL-12, and priming of antigen-specific T cells
Which controls?A control antibody matched for isotype and Fc format, a stated crosslinking condition and an antibody-free eDC
How is the screen qualified?Agree assay-performance criteria (for example Z′ and CV) and lot-to-lot reproducibility before the screen starts
Discuss a screening project

APC drug discovery study design

Choose the system around the effect you intend to measure. A change in a T cell readout may reflect altered APC function, effector cell behavior, target cell susceptibility or viability. The study design should distinguish the relevant possibilities.

Scientific support for your experiment

Discuss your antigen, HLA context, study controls and custom engineering requirements.

Explore scientific support